Active metabolite from Tamiflu® solution is bioequivalent to that from capsule delivery in healthy volunteers: A cross-over, randomised, open-label study

This publication has 21 references indexed in Scilit:

• H5N1 influenza and the implications for Europe
  BMJ, 2005
• Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir
  Current Medical Research and Opinion, 2005
• Confronting the avian influenza threat: vaccine development for a potential pandemic
  The Lancet Infectious Diseases, 2004
• Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis
  The Journal of Infectious Diseases, 2004
• Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations
  Archives of internal medicine (1960), 2003
• Effectiveness of Oseltamivir in Preventing Influenza in Household ContactsA Randomized Controlled Trial
  JAMA, 2001
• Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
  The Lancet, 2000
• Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
  JAMA, 2000
• Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection
  Antimicrobial Agents and Chemotherapy, 1998
• IMPACT OF EPIDEMIC TYPE A INFLUENZA IN A DEFINED ADULT POPULATION
  American Journal of Epidemiology, 1980